Exploratory Study Evaluating the Effects of Darifenacin on Nocturia, Sleep and Daytime Wakefulness

NCT01018225 | Withdrawn Phase 4

• 1 other identifier: CRC090001
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this study is to evaluate the efficacy of darifenacin in the treatment of moderate to severe nocturia in patients with overactive bladder and who do not have non-urologic causes of nocturia.

Conditions

Nocturia

Study Arms (2)

darifenacin

EXPERIMENTAL

Drug: darifenacin

Sugar Pill

PLACEBO COMPARATOR

Drug: Placebo

Interventions

darifenacin DRUG

7.5 or 15 mg darifenacin, once a day for 6 weeks

Also known as: Enablex

darifenacin

Placebo DRUG

Placebo pill, once a day, for six weeks

Sugar Pill

Eligibility Criteria

• Age: 21 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject must be aged 21-70, inclusive.
• Subject mush have given written, personally signed and dated informed consent.
• Subject must be diagnosed with overactive bladder.
• Subject must have a nocturia frequency of greater than or equal to 3 episodes a night.
• Subject must be male or non-pregnant, non-lactating female who agrees to comply with applicable contraceptive requirements.
• Subject understands and is able, will a nd and likely to fully comply with study procedures and restrictions.

You may not qualify if:

• Subject has any concurrent chronic or acute illness or unstable medical condition either treated or untreated that could confound the results of safety assessments, increase risk to the subject or lead to difficulty complying with the protocol.
• The subject has a known or suspected allergy, hypersensitivity, or other medical contraindications to darifenacin (Enablex®) (or its components).
• The subject has concomitant diseases in which the use of anticholinergic drugs is contraindicated, e.g. urinary retention, bladder obstruction, gastric retention and other severe decreased gastrointestinal motility conditions, uncontrolled narrow-angle glaucoma, myasthenia gravis, severe hepatic impairment (Child Pugh C), severe ulcerative colitis, toxic megacolon, and patients who are at risk for these conditions.
• Subject is taking another drug which is considered to have significant anticholinergic activity.
• Use of drugs known to effect cognition, alertness or drowsiness, such as benzodiazepines, sedating antihistamines, opioids, or other sedative hypnotic drugs.
• Subject has moderate to severe obstructive sleep apnea (Apnea/Hypopnea Index ≥ 15)
• Subject has a medical condition other than OAB that is the most likely cause of the subject's nocturia (e.g., primary sleep disorder, polydipsia, polyuria).
• Subject has taken another investigational drug or taken part in a clinical trial within the last 30 days prior to Screening.
• The female subject is pregnant or lactating.
• Subjects with a urine drug screen positive for stimulants, barbiturates, hallucinogens, opiates, cocaine, cannabis, or amphetamines

Sponsors & Collaborators

• Cognitive Research Corporation: lead
• Novartis Pharmaceuticals: collaborator

MeSH Terms

Conditions

Nocturia

Interventions

darifenacin

Condition Hierarchy (Ancestors)

Lower Urinary Tract Symptoms; Urological Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: phase 4
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: November 20, 2009
• First Posted: November 23, 2009
• Study Start: November 1, 2009
• Study Completion: July 1, 2010
• Last Updated: April 13, 2016

Record last verified: 2016-04